MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy
Rhea-AI Summary
MiNK Therapeutics (NASDAQ: INKT) announced that an abstract on its investigational allogeneic iNKT cell therapy agenT-797 was accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, May 11-15, 2026, in Boston.
Presenter Terese C. Hammond, MD, will present data titled "AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS." Session timing and poster location will be posted on the ASGCT conference program website in mid-April.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – INKT
On the day this news was published, INKT gained 1.14%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peer moves are mixed: HOWL up 14.59%, ARTV up 3.68%, ALXO down 2.94%, while ACET and PRLD were flat. The momentum scanner only flags PRLD moving down, suggesting today’s setup around INKT is more stock-specific than a broad sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Conference abstract news | Positive | +0.4% | ATS 2026 abstract acceptance featuring agenT-797 in pulmonary infection. |
| Mar 31 | Earnings and pipeline | Positive | +0.1% | Q4/FY25 results with cash update and advancing Phase 2 programs. |
| Mar 17 | Earnings date notice | Positive | +4.9% | Scheduled FY25 results call and platform expansion collaboration details. |
| Mar 10 | Strategic collaboration | Positive | +29.3% | C-Further partnership for PRAME-targeted TCR-engineered iNKT therapy. |
| Mar 10 | Partner program launch | Positive | +29.3% | C-Further paediatric oncology programs including PRAME iNKT with MiNK. |
Recent positive or strategic news has generally aligned with same-direction price gains.
Over the last few weeks, MiNK has highlighted multiple catalysts across its iNKT platform. On Mar 10, a PRAME‑targeted pediatric cancer collaboration and related C‑Further announcement coincided with a 29.28% move. Subsequent earnings on Mar 31 detailed $13.4M year‑end cash and added funding, with modest gains. Conference‑related communications on Mar 17 and Apr 1 also saw positive reactions. Today’s ASGCT abstract acceptance continues this cadence of scientific visibility events.
Regulatory & Risk Context
An effective S-3 shelf filed on Nov 7, 2025 registers up to $150,000,000 in securities, with a related ATM program for up to $50,000,000 of common stock through B. Riley Securities. Based on a public float of $35,031,699, current ATM capacity is limited to $6,641,284, and no usage has been reported yet.
Market Pulse Summary
This announcement adds another scientific visibility event for agenT‑797, highlighting context‑dependent activity in cancer and ARDS at ASGCT 2026. It follows recent collaborations, clinical updates, and conference abstracts that have generally coincided with positive price moves. Investors may watch for detailed data at the meeting, alongside balance sheet metrics such as $13.4M year‑end cash, the additional $3.0M raised, and potential utilization of the $150,000,000 shelf and $50,000,000 ATM program.
Key Terms
allogeneic medical
iNKT cell therapy medical
allo-iNKT medical
ARDS medical
AI-generated analysis. Not financial advice.
NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today announced that an abstract featuring its investigational iNKT cell therapy, agenT-797, has been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, taking place May 11-15, 2026, in Boston, MA.
Presentation Details:
- Abstract Title: AgenT-797 Allogeneic iNKT Cell Therapy Demonstrates Adaptive Immune Modulation in Cancer and ARDS
- Presenter: Terese C. Hammond, MD; Program Director of Pulmonary and Critical Care, Kaweah Health Medical Center; Head of Inflammatory and Pulmonary Diseases, MiNK Therapeutics
Additional information on the poster presentation including session location and timing details will be made available by ASGCT via the ASGCT Annual Meeting conference program website in mid-April.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK’s proprietary platform is designed to restore immune balance and drive cytotoxic responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK’s lead candidate, agenT-797, is an off-the-shelf iNKT cell therapy currently in clinical development for GVHD, solid tumors, and severe pulmonary inflammation. With a scalable cryopreserved manufacturing process and differentiated biology bridging innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies. For more information, visit www.minktherapeutics.com or follow us on X @MiNK_iNKT.
About agenT-797
AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy that harnesses the dual power of innate and adaptive immunity. iNKTs function as “master regulators,” combining the cytotoxic capabilities of NK cells with T-cell–like antigen recognition and memory. This unique biology enables a robust, pathogen-agnostic immune response that can be directed against hard-to-treat tumors. Manufactured by MiNK Therapeutics in Lexington, MA, agenT-797 is a scalable, off-the-shelf product designed to provide accessible, transformative treatment options. In clinical trials, agenT-797 can bolster peripheral memory T-cell activation, enhance tumor infiltration, and potentially improve outcomes for patients with solid cancers (Cytryn et al. AACR IO 2024, Oncogene. 2024) and to combat inflammation in critically ill patients with severe respiratory pathology (Nature Communications. 2024).
Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding the therapeutic potential, safety, and anticipated benefits of agenT-797; clinical trial design, timing, and enrollment; and MiNK’s broader development plans. These statements are subject to risks and uncertainties detailed in MiNK’s most recent filings with the Securities and Exchange Commission. MiNK cautions investors not to place undue reliance on these statements, which speak only as of the date of this release.
Contacts:
Investor Contact: 917-362-1370 | investor@minktherapeutics.com
Media Contact: 781-674-4428 | communications@minktherapeutics.com
Source: MiNK Therapeutics
